Experienced in Congenital Antithrombin 3 Deficiency

Ingrid Pabinger-Fasching

Vienna, AT 
Experienced in Congenital Antithrombin 3 Deficiency
Vienna, AT 
OverviewLocationsClinical Research

Overview

Ingrid Pabinger-Fasching practices in Vienna, Austria. Ms. Pabinger-Fasching is rated as an Experienced expert by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. Her top areas of expertise are Blood Clots, Hemophilia A, Venous Thromboembolism (VTE), and Hemophilia B.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Congenital Antithrombin 3 Deficiency.

Gender
Female

Locations

Vienna, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: BAX-888 Adeno-Associated Virus Serotype 8 Vector B-Domain Deleted Factor VIII Vaccine
Study Phase: Phase 1/Phase 2
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
Enrollment Status: Terminated
Publish Date: May 19, 2022
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

46 Total Publications

The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points.
The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points.
Journal: ESMO open
Published: August 22, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pabinger-Fasching's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile